Key Takeaways
- • Montagu Private Equity has agreed to sell French drug-delivery device manufacturer Nemera to French private equity firm Astorg, with the transaction valuing the company at approximately €1 billion ($1.2 billion).
- • Montagu will reinvest in Nemera as an equal partner alongside Astorg and the company's management team, maintaining a stake in the business through the next growth phase rather than executing a complete exit.
- • Nemera specializes in parenteral drug delivery devices, including pen injector platforms (PenSET and PenDIA) designed to accommodate GLP-1 drugs with spring-assisted injection mechanisms, positioning the company at the center of the high-growth diabetes and weight-loss pharmaceutical market.
- • LGT Capital Partners-advised entities have acquired a minority stake in Nemera, broadening the cap table beyond the primary Montagu-Astorg partnership and signaling institutional confidence in the drug delivery device sector.
- • The transaction reflects sustained private equity interest in medical device manufacturers benefiting from accelerating GLP-1 adoption, as pharmaceutical companies including Novo Nordisk pursue complementary device acquisitions in the same therapeutic space.
Summary
Montagu Private Equity has agreed to sell its stake in Nemera, a leading French manufacturer of drug delivery devices, to fellow private equity firm Astorg in a transaction valuing the company at approximately €1 billion ($1.2 billion). Rather than a complete exit, the deal structures Montagu as an equal co-investor alongside Astorg and Nemera's management team, enabling continued participation in the company's growth trajectory.
Nemera designs, develops, and manufactures parenteral drug delivery systems for the pharmaceutical, biotech, and generic industries. The company's product portfolio includes inhalers, nasal spray containers, eye drop dispensers, and critically, pen injector platforms specifically engineered for GLP-1 drug administration. The company's PenSET and PenDIA platforms feature spring-assisted injection mechanisms designed to optimize patient experience with GLP-1 therapeutics, positioning Nemera to capture share in the rapidly expanding diabetes and weight-loss pharmaceutical market.
The transaction reflects broader private equity appetite for medical device manufacturers positioned within high-growth therapeutic categories. The deal's timing aligns with intensified competition among pharmaceutical manufacturers to secure proprietary or exclusive drug delivery device capabilities. Novo Nordisk has pursued parallel strategy, entering discussions to acquire French device-maker Biocorp, underscoring how large pharma players view device partnerships and acquisitions as central to competitive positioning in GLP-1 markets.
The involvement of LGT Capital Partners-advised entities, which have acquired a minority stake in Nemera, expands the transaction's cap table and reflects institutional investor confidence in the drug delivery device sector's secular tailwinds. The reinvestment structure by Montagu alongside new institutional capital suggests conviction that Nemera's growth phase extends meaningfully beyond the current transaction, potentially signaling anticipated follow-on investment or operational value creation opportunities.
Nemera designs, develops, and manufactures parenteral drug delivery systems for the pharmaceutical, biotech, and generic industries. The company's product portfolio includes inhalers, nasal spray containers, eye drop dispensers, and critically, pen injector platforms specifically engineered for GLP-1 drug administration. The company's PenSET and PenDIA platforms feature spring-assisted injection mechanisms designed to optimize patient experience with GLP-1 therapeutics, positioning Nemera to capture share in the rapidly expanding diabetes and weight-loss pharmaceutical market.
The transaction reflects broader private equity appetite for medical device manufacturers positioned within high-growth therapeutic categories. The deal's timing aligns with intensified competition among pharmaceutical manufacturers to secure proprietary or exclusive drug delivery device capabilities. Novo Nordisk has pursued parallel strategy, entering discussions to acquire French device-maker Biocorp, underscoring how large pharma players view device partnerships and acquisitions as central to competitive positioning in GLP-1 markets.
The involvement of LGT Capital Partners-advised entities, which have acquired a minority stake in Nemera, expands the transaction's cap table and reflects institutional investor confidence in the drug delivery device sector's secular tailwinds. The reinvestment structure by Montagu alongside new institutional capital suggests conviction that Nemera's growth phase extends meaningfully beyond the current transaction, potentially signaling anticipated follow-on investment or operational value creation opportunities.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.